Collectively, these results suggest that PLAU may be an independent biomarker for predicting the outcomes of HNSCC patients and potentially contribute to tumour immunosuppression either in concert with or via TNFRSF12A [39]. The gene discussed is TNFRSF12A; the disease is head and neck squamous cell carcinoma.